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participate.Percutaneous Coronary Intervention Versus Medical Therapy in Stable Coronary
Artery Disease: The Unresolved Conundrum993Stephen E. Epstein, Ron Waksman, Augusto D. Pichard, Kenneth M. Kent, Julio A. Panza
One of the major dilemmas facing physicians is what diagnostic and therapeutic
approaches should be recommended to those stable coronary artery disease patients
whose symptoms are adequately controlled on medical therapy. Such patients
should: 1) all undergo percutaneous coronary intervention (PCI); 2) all have therapy
limited to optimal medical therapy; or 3) have PCI be performed, but PCI limited
to only certain subsets of patients. Review of all recent meta-analyses of prospective
randomized trials comparing outcomes of medical therapy and PCI indicates that
no difference exists between PCI and medical therapy in nonfatal myocardial
infarction or in all-cause or cardiovascular mortality. Thus, clinical equipoise exists,
making it appropriate for the responsible physician to weigh additional clinical and
angiographic factors in formulating a recommendation to the patient, even though
deﬁnitive evidence-based data are not as yet available.(continued on A-30)
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A-30CLINICAL RESEARCH Five-Year Clinical and Functional Multislice Computed Tomography Angiographic
Results After Coronary Implantation of the Fully Resorbable Polymeric
Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease:
The ABSORB Cohort A Trial999Yoshinobu Onuma, Dariusz Dudek, Leif Thuesen, Mark Webster, Koen Nieman,
Hector M. Garcia-Garcia, John A. Ormiston, Patrick W. Serruys
The long-term safety and efﬁcacy after implantation of a fully resorbable
everolimus-eluting scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California)
remains to be documented. In the ABSORB cohort A trial, 30 patients with
a single de novo coronary artery lesion were treated with the fully resorbable ever-
olimus-eluting Absorb scaffold and underwent multi-slice computed tomography
(MSCT) angiography at 18 months and 5 years. At 5 years, the ischemia-driven
major adverse cardiac event rate was 3.4%. Clopidogrel was discontinued in all but
one patient. Eighteen patients underwent MSCT angiography at 5 years. All
scaffolds were patent with a median minimal lumen area of 3.25 mm2 (interquartile
range [IQR]: 2.20 to 4.30). Noninvasive fractional ﬂow reserve (FFR) analysis was
feasible in 13 of the 18 scans, which yielded a median distal FFR of 0.86 [IQR: 0.82
to 0.94]. The low event rate at 5-years suggests sustained safety after the implan-
tation of a fully bioresorbable Absorb everolimus-eluting scaffold. Noninvasive
assessment of the coronary artery with an option of functional assessment could be
the alternative to invasive imaging after treatment of coronary narrowing with such
a polymeric bioresorbable scaffold.
See additional content in the online version of this issue.EDITORIAL COMMENTThe Synergy Between Percutaneous Therapies and Noninvasive
Diagnostic Imaging1010James K. Min(continued on A-31)
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A-31A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary
Stent System in the Treatment of Patients With Multivessel Coronary Artery
Disease: The EXECUTIVE Trial (EXecutive RCT: Evaluating XIENCE V in a
Multi Vessel Disease)1012Flavio Ribichini, Michele Romano, Renato Rosiello, Luigi La Vecchia, Ester Cabianca,
Giuseppe Caramanno, Diego Milazzo, Paolo Loschiavo, Stefano Rigattieri, Salvatore Musarò,
Bruno Pironi, Antonio Fiscella, Francesco Amico, Ciro Indolﬁ, Carmen Spaccarotella,
Antonio Bartorelli, Daniela Trabattoni, Francesco Della Rovere, Andrea Rolandi,
Federico Beqaraj, Riccardo Belli, Pietro Sangiorgio, Rosvaldo Villani, Andrea Berni,
Imad Sheiban, Maria Josè Lopera Quijada, Barbara Cappi, Licia Ribaldi, Corrado Vassanelli,
on behalf of the EXECUTIVE Trial Investigators
The Executive trial is a randomized multicenter trial that assessed angiographic
efﬁcacy of the XIENCE V everolimus-eluting stent (EES) compared with the
TAXUS Libertè paclitaxel-eluting stent (PES) in 200 patients with multivessel
coronary artery disease (MV-CAD) and a prospective, open-label, single-arm,
controlled registry that analyzed the clinical outcome of EES at 1-year follow-up in
400 MV-CAD patients. Implantation of XIENCE V EES resulted in signiﬁcantly
lower late loss at 9 months compared with the PES (0.027  0.485 mm vs.
0.225  0.507 mm, p ¼ 0.001) and a composite of major adverse cardiac events of
9.2% in the registry. This is the ﬁrst randomized trial to our knowledge dedicated to
the comparison of 2 different DES among patients with MV-CAD
See additional content in the online version of this issue.EDITORIAL COMMENTComplex Coronary Artery Disease: Would Outcomes From the SYNTAX (Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery)
Trial Have Differed With Newer-Generation Drug-Eluting Stents?1023Vasim Farooq, Patrick W. Serruys(continued on A-32)
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A-32First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting
Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and
a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the
Native Coronary Arteries)1026John Ormiston, Mark Webster, James Stewart, Mathias Vrolix, Robert Whitbourn,
Dennis Donohoe, Charlene Knape, Alexandra Lansky, Guilherme F. Attizzani, Peter Fitzgerald,
David E. Kandzari, William Wijns
The permanent polymer coating of drug-eluting stents has been linked to vascular
inﬂammation, delayed healing, and long-term adverse clinical events. We examined
the performance of a new absorbable polymer sirolimus-eluting cobalt chromium
stent in 30 patients with >50% coronary stenoses who underwent serial angiog-
raphy, intravascular ultrasound, and optical coherence tomography. The median in-
stent late lumen loss was 0.03 mm, 0.10 mm, 0.08 mm, and 0.08 mm, at 4, 6, and 8
and 18 months, respectively. The volume obstruction by intravascular ultrasound
increased from a median of 5.3% to 9.1% between 4 and 6 months and remained
nearly unchanged thereafter. The only major adverse cardiac event was a nontarget
vessel–related myocardial infarction. These observations warrant further investiga-
tions in a larger population.
See additional content in the online version of this issue.Serial Assessment of Vessel Interactions After Drug-Eluting Stent Implantation in
Unprotected Distal Left Main Coronary Artery Disease Using Frequency-Domain
Optical Coherence Tomography1035Yusuke Fujino, Guilherme F. Attizzani, Hiram G. Bezerra, Wei Wang, Satoko Tahara,
Hirosada Yamamoto, Daniel Chamie, Tomoaki Kanaya, Emile Mehanna, Kensuke Takagi,
Sunao Nakamura, Marco A. Costa
Frequency-domain optical coherence tomography (FD-OCT) assessments have
been used as surrogates for drug-eluting stent safety; however, there are no FD-
OCT studies in unprotected left main coronary artery (ULM). We prospectively
enrolled 33 consecutive patients with ULM disease involving distal bifurcation.
FD-OCT assessments were performed after percutaneous coronary intervention
and at 9-month follow-up, and 3 different segments of ULM were compared:
distal; bifurcation; and ostial-body. While the ostial-body segment showed more
uncovered and malapposed struts, the neointimal hyperplasia area was equivalent
between segments. In addition, acute malapposition led to an impact in drug-
eluting stent-vessel interactions at 9-month follow-up.
See additional content in the online version of this issue.(continued on A-33)
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A-33Prognostic Value of Microvascular Resistance Index Immediately After Primary
Percutaneous Coronary Intervention on Left Ventricular Remodeling in Patients With
Reperfused Anterior Acute ST-Segment Elevation Myocardial Infarction1046Hironori Kitabata, Takashi Kubo, Kohei Ishibashi, Kenichi Komukai, Takashi Tanimoto,
Yasushi Ino, Manabu Kashiwagi, Yuichi Ozaki, Yasutsugu Shiono, Kunihiro Shimamura,
Makoto Orii, Kumiko Hirata, Atsushi Tanaka, Toshio Imanishi, Takashi Akasaka
We examined the relationship between the microvascular resistance index (MVRI)
immediately after primary percutaneous coronary intervention and left ventricular
(LV) remodeling in patients with reperfused anterior acute myocardial infarction.
MVRI was calculated as the ratio of mean distal pressure to average peak ﬂow
velocity during maximal hyperemia. Left ventricular end-diastolic volume
(LVEDV) at 8 months and the percentage of increase or decrease in LVEDV were
signiﬁcantly greater in patients with increased MVRI. LV remodeling was more
often in the high MVRI group. MVRI correlated signiﬁcantly with the percentage
of change in LVEDV. Moreover, MVRI was the only independent predictor of LV
dilation. MVRI predicts LV remodeling after reperfused acute myocardial
infarction.Remote Ischemic Post-Conditioning of the Lower Limb During Primary Percutaneous
Coronary Intervention Safely Reduces Enzymatic Infarct Size in Anterior Myocardial
Infarction: A Randomized Controlled Trial1055Gabriele Crimi, Silvia Pica, Claudia Raineri, Ezio Bramucci, Gaetano M. De Ferrari,
Catherine Klersy, Marco Ferlini, Barbara Marinoni, Alessandra Repetto, Maurizio Romeo,
Vittorio Rosti, Margherita Massa, Arturo Raisaro, Sergio Leonardi, Paolo Rubartelli,
Luigi Oltrona Visconti, Maurizio Ferrario
A total of 100 patients presenting with anterior ST-segment elevation myocardial
infarction (STEMI) were randomized to remote postconditioning (RIPC)þ primary
PCI (pPCI) or pPCI alone. RIPC consisted of 3  50/50 ischemia/reperfusion of
the leg at the time of pPCI. A total of 96 patients were analyzed. RIPC reduced
primary endpoint of enzimatic infarct size area under the curve of creatine kinase-
myocardial band by 20% (95% CI: 0.2% to 28.7%, p ¼ 0.043). Edema volume
assessed with T2 weighted (T2W) magnetic resonance imaging was 37  16 cc
in RIPC þ pPCI and 47  22 cc in pPCI (p ¼ 0.049). ST-segment resolution
50% (STR50) was 66% in RIPCþ pPCI and 37% in controls (p¼ 0.015). In patients
with anterior STEMI, RIPC at the time of primary PCI reduced enzymatic infarct
size and was associated with an improvement of T2W edema and STR50.
See additional content in the online version of this issue.(continued on A-34)
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A-34Achieving Sustainable First Door-to-Balloon Times of 90 Minutes for Regional
Transfer ST-Segment Elevation Myocardial Infarction1064B. Hadley Wilson, Angela D. Humphrey, John C. Cedarholm, William E. Downey,
Robert H. Haber, Glen J. Kowalchuk, Michael J. Rinaldi, Denise A. Miller, Jennifer L. Saraﬁn,
J. Lee Garvey
A network approach to transfer ST-segment elevation myocardial infarction
(STEMI) patients can achieve durable ﬁrst door-to-balloon times (1st D2B) for
percutaneous coronary intervention (PCI) within 90 min. Included were transfer
STEMI patients from 9 network hospitals treated in 2007 compared with 2008
to 2011 after installing initiatives. The median 1st D2B decreased from 109.5 to
88.0 min (p < 0.0001), and the percentage under 90 min increased from 22.8% to
55.9% (p < 0.0001). Length of stay and in-hospital mortality remained low at
3.0 days and under 4%, respectively. A system-wide network program can achieve
sustained (over 4 years) 1st D2B times of <90 min.Chronic Obstructive Pulmonary Disease in Patients Undergoing Transcatheter
Aortic Valve Implantation: Insights on Clinical Outcomes, Prognostic Markers,
and Functional Status Changes1072Michael Mok, Luis Nombela-Franco, Eric Dumont, Marina Urena, Robert DeLarochellière,
Daniel Doyle, Jacques Villeneuve, Mélanie Côté, Henrique B. Ribeiro, Ricardo Allende,
Jerôme Laﬂamme, Hugo DeLarochellière, Louis Laﬂamme, Ignacio Amat-Santos,
Philippe Pibarot, François Maltais, Josep Rodés-Cabau
The objective of this study was to determine the effects of chronic obstructive
pulmonary disease (COPD) on clinical outcomes after transcatheter aortic valve
implantation (TAVI). A total of 319 consecutive patients (29.5% with COPD) who
underwent TAVI were studied. COPD was an independent predictor of 1-year
mortality after TAVI (p ¼ 0.026). COPD patients exhibited less (p ¼ 0.036)
improvement in New York Heart Association functional class at follow-up. Among
COPD patients, a shorter 6-min walk test distance predicted cumulative mortality
(p ¼ 0.013) whereas poorer baseline spirometry results (FEV1 [forced expiratory
volume after the ﬁrst second of expiration]) determined a higher rate of peri-
procedural pulmonary complications (p ¼ 0.040). The TAVI treatment was futile
(death or no functional class improvement at 6 months) in 42.5% of COPD
patients, and a 6-min walk test distance <170 m best determined the lack of beneﬁt
after TAVI (p ¼ 0.002).(continued on A-35)
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A-35Does the Presence of Accessory Renal Arteries Affect the Efﬁcacy of
Renal Denervation?1085Dani Id, Benjamin Kaltenbach, Stefan C. Bertog, Marius Hornung, Ilona Hofmann,
Laura Vaskelyte, Horst Sievert
We sought to compare the effect of renal denervation in patients with single renal
arteries to those with accessory renal arteries. There was a signiﬁcant reduction in
both ofﬁce and ambulatory blood pressures after renal denervation in patients with
single renal arteries. However, there was a less pronounced blood pressure reduction
in patients with accessory renal arteries, regardless of whether all accessory renal
arteries were treated with renal denervation or not. In these patients, the blood
pressure reduction did not reach signiﬁcance. Hence, blood pressure reduction is
less pronounced after renal denervation in the presence of accessory renal arteries.EDITORIAL COMMENTCatheter-Based Renal Denervation: The Black Box Procedure 1092Felix Mahfoud, Deepak L. BhattPhysicians’ Radiation Exposure in the Catheterization Lab: Does the Type of
Procedure Matter?1095Maja Ingwersen, Anna Drabik, Ulrike Kulka, Ursula Oestreicher, Simon Fricke,
Hans Krankenberg, Carsten Schwencke, Detlef Mathey
This study evaluated the effect of different types of catheterization lab procedures
on operators’ radiation exposure by using real-time dosimetry. We found a 1.4- to
2.3-fold increased effective radiation dose to the body from below-the-knee, upper
limb, and pelvic procedures compared with doses from coronary angiography.
Operators’ eye doses from these peripheral procedures were signiﬁcantly higher than
those from coronary angiography. Hands were exposed to the highest radiation
doses during pelvic procedures. We conclude that endovascular peripheral proce-
dures are accompanied with a higher radiation exposure of catheterization lab
operators than coronary procedures are. Protection devices should be used wherever
applicable.JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.(continued on A-36)
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A-36IMAGES IN
INTERVENTIONPercutaneous Closure of an Aortic Pseudoaneurysm Due to Saphenous Vein Graft
Dehiscence With an Amplatzer Vascular Plug1103Satya S. Shreenivas, Scott Lilly, Nimesh D. Desai, Ali Farooki, Albert T. Cheung,
Michael A. Acker, Howard C. Herrmann, Saif Anwaruddin
This article has accompanying videos that can be viewed in the online
version of this issue.Anterograde Percutaneous Coronary–Cameral Fistula Closure Employing
a Guide-in-Guide Technique1105Todd L. Kiefer, John Vavalle, Sharif Halim, Prashant Kaul, J. Larry Klein, Lynne H. Hurwitz,
Jeffrey G. Gaca, J. Kevin Harrison
This article has accompanying videos that can be viewed in the online
version of this issue.EDITOR’S PAGE Surgeons and Cardiologists: The Indispensable Team 1108Spencer B. King IIICORRECTION 1110
